REMEDi4ALL is an EU-funded
research initiative to drive forward
the repurposing of medicines in Europe.
The platform has the potential to bring down times and costs of drug development by focusing on already approved, discontinued, shelved or investigational therapeutics.
Expertise and Collaboration
The REMEDi4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement will closely collaborate to make drug repurposing mainstream.
It will receive 23M euros from Horizon Europe over the next 5 years
Click the image to enlarge
State-of-the-art platform
Build a state-of-the-art platform to provide expertise and services across the complete value chain (scientific, methodological, financial, legal, regulatory, intellectual property) for patient-centric medicine repurposing at every development stage and in any disease area.
Train & Educate
Train and educate the next generation of researchers, clinicians, patients, policymakers, regulators and funders in cutting-edge drug repurposing tools and processes.
Artificial Intelligence
Assemble advanced in silico tools for Machine Learning (ML) and Artificial Intelligence (AI), open datasets and tools and expertise required to understand the mechanism of action of specific medicines.
Global Community
Create a global community of practice connected in a think-tank-like environment through impactful multidisciplinary activities and events and favour dialogue and debate to advance policy and fair access to repurposed medicines across the EU.
REMEDi4ALL Partners & Associated partners
